eMed raises $200 million in funding to build an AI agent platform and offer new models to employers, including GLP-1 therapeutics programs.
This funding round raised the company’s valuation to $2 billion. AON Consulting led the round along with notable investors former NFL player Tom Brady, Founding Chief Wellness Officer Jeff Aronin, and Founder, Chairman, and CEO of Paragon Biosciences. Ara Cohen, co-founder and co-managing member of Knighthead Capital Management; Antonio Gracias, Founder and CEO of Valor Equity Partners. Joe Lonsdale, Founder and Managing Partner of 8VC and Co-Founder of Palantir. RJ Melman, CEO of Lettuce Entertain You Restaurants, Tom Ricketts, Chairman of the Chicago Cubs. Linda Yaccarino, former CEO of X and current CEO of eMed;
The company plans to use the new funding to support and fund a new headcount model designed to help employers bend the healthcare cost curve. According to the company, GLP-1 therapeutics are the most requested benefit in the workplace, but only one in five companies offers the benefit.
“I believe that eMed’s empathetic agent AI platform, combined with the power of our employees and partners, represents a true winning formula. That belief is why I chose to invest both my time and capital in the company as founding chief wellness officer,” Brady said in a statement.
The company offers a clinically supervised GLP-1 program for employers. eMed boasts a 90% member compliance rate, more than double the industry standard, with an average weight loss of 21 pounds. Additionally, 99% of program participants saw improvement in at least one key biomarker within six months.
